Importance of prognostic factors in the treatment of CLL and how to assess them
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.
Why drug combinations are the future of treatment in CLL
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian